Mitral Regurgitation Management: Current Knowledge and Future Perspectives

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (20 December 2023) | Viewed by 4484

Special Issue Editors


E-Mail Website
Guest Editor
Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
Interests: clinical cardiology; interventional cardiology; heart failure; valvular heart disease

E-Mail Website
Guest Editor
Department of Cardiovascular Explorations and Physiology—Heart Valve Center, Lille University Hospital, Lille, France
Interests: clinical cardiology; structural heart disease; multimodality imaging; interventional echocardiography

E-Mail Website
Guest Editor
Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Interests: interventional cardiology; structural heart disease; valvular heart disease

Special Issue Information

Dear Colleagues,

The scope of this Special Issue is to provide an overview of the current knowledge and future perspectives on the management of mitral regurgitation (MR). Over the last decade, many significant advances have been achieved in the diagnosis of MR, including the recognition of an additional MR mechanism (atrial functional) and the adoption of new imaging modalities and indexes to assess and grade MR severity. Additionally, the transcatheter approach for MR treatment is on the rise, and several transcatheter technologies are currently in use or under investigation. As such, many patients may benefit from an interventional treatment of their valvular heart disease. Therefore, interest in understanding the mechanism and treatment of MR is growing exponentially.

We encourage authors to submit an original article or a state-of-the-art review to this Special Issue.

Dr. Andrea Scotti
Dr. Augustin Coisne
Dr. Sebastian Ludwig
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mitral regurgitation
  • heart failure
  • outcomes
  • transcatheter mitral valve repair
  • transcatheter mitral valve replacement

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 1052 KiB  
Article
Sex-Specific Disparities in Outcomes of Transcatheter Edge-to-Edge Repair for Mitral Regurgitation: A Multicenter “Real-World” Analysis
by Felix Ausbuettel, Sebastian Barth, Georgios Chatzis, Kiarash Sassani, Dieter Fischer, Sebastian Weyand, Julian Mueller, Harald Schuett, Bernhard Schieffer, Ulrich Luesebrink and Christian Waechter
J. Clin. Med. 2023, 12(23), 7231; https://doi.org/10.3390/jcm12237231 - 22 Nov 2023
Viewed by 1009
Abstract
Background: mitral regurgitation (mr) is the most common valvular heart disease (vhd) in the elderly and tends to be more prevalent in women. while relevant sex differences in outcomes are evident in surgically treated collectives, there are very limited and conflicting sex-specific data [...] Read more.
Background: mitral regurgitation (mr) is the most common valvular heart disease (vhd) in the elderly and tends to be more prevalent in women. while relevant sex differences in outcomes are evident in surgically treated collectives, there are very limited and conflicting sex-specific data for the growing cohort of patients undergoing transcatheter edge-to-edge repair (teer). Objective: to investigate whether sex impacts procedural safety and efficacy, and in-hospital- and long-term outcomes, after teer for mr. Methods: in a multicenter observational cohort study, patients who underwent teer were stratified by sex and relevant outcome measures, and analyzed using multivariable cox regression and propensity score matching (psm). Results: a total of 821 patients were analyzed, of whom 37.4% (307/821) were female. compared to male patients, females were significantly older (77 ± 8.5 vs. 80.4 ± 6.7 years, p = 0.03), and had less coronary artery disease (cad, 67.7% vs. 53.1%, p < 0.0001) and a higher proportion of preserved left ventricular function (lvef > 50%, 32.5% vs. 50.5%, p > 0.0001). safety and efficacy of the teer procedure and in-hospital mortality did not differ between the sexes. after psm, women showed significantly better survival 3 years after teer compared to men (60.7% vs. 54.2%, p = 0.04) and a lower risk of all-cause death according to multiple cox regression (hr 0.8, 95% ci 0.6–0.9, p = 0.02). after sex-specific stratification for concomitant atrial fibrillation (af), the most common comorbidity in the present collective, women with af experience significantly worse adjusted survival compared to women without af (53.9% vs. 75.1%, p = 0.042) three years after teer and lose the survival advantage over men. Conclusions: female patients are older and less comorbid than males undergoing TEER. The TEER procedure is equally safe and effective in both sexes. While in-hospital mortality did not differ, female patients experienced a significantly better adjusted long-term survival compared to male patients. Concomitant AF offsets the prognostic advantage of females over males and, in contrast to males, significantly impairs long-term survival in women undergoing TEER. Further research is warranted to elucidate underlying causes for the observed sex disparities and to develop sex-tailored treatment recommendations. Full article
Show Figures

Figure 1

11 pages, 1263 KiB  
Article
Predictors of Improvement in Concomitant Tricuspid Regurgitation Following Transcatheter Edge-to-Edge Mitral Valve Repair
by Matthias Gröger, Kai Hirsch, Dominik Felbel, Michael Paukovitsch, Leonhard Moritz Schneider, Sinisa Markovic, Wolfgang Rottbauer and Mirjam Keßler
J. Clin. Med. 2023, 12(19), 6191; https://doi.org/10.3390/jcm12196191 - 25 Sep 2023
Viewed by 707
Abstract
Background: Improvement in concomitant tricuspid regurgitation (TR) after mitral valve transcatheter edge-to-edge repair (M-TEER) for mitral regurgitation (MR) occurs frequently; however factors determining the post-procedural course of TR are not well understood. We investigated the parameters associated with TR improvement after M-TEER. Methods [...] Read more.
Background: Improvement in concomitant tricuspid regurgitation (TR) after mitral valve transcatheter edge-to-edge repair (M-TEER) for mitral regurgitation (MR) occurs frequently; however factors determining the post-procedural course of TR are not well understood. We investigated the parameters associated with TR improvement after M-TEER. Methods and Results: A total of 300 patients were consecutively included in this retrospective analysis. MR and TR severity as well as heart chamber metrics were assessed before the procedure and at follow-up. Device success was achieved in 97.3% of patients. TR decreased in 30.2% of patients. Patients with improved TR were more often female, had more severe TR at baseline, and their right heart dimensions at baseline trended to be smaller. Female sex (odds ratio (OR) 2.997), baseline MR-Grade (OR 3.181) and baseline TR-Grade (OR 2.653) independently predicted TR reduction. More pronounced right heart reverse remodeling was observed in patients with improved TR. TR regression independently predicted lower mortality (hazard ratio (HR) 0.333, 95% confidence interval 0.112–0.996, p = 0.049). Conclusions: A reduction in concomitant TR severity after M-TEER occurred mainly in females and in patients with high-grade TR and MR at baseline. TR regression is associated with better survival after M-TEER. Full article
Show Figures

Figure 1

10 pages, 862 KiB  
Article
New Echocardiographic Parameters Predicting Successful Trans-Ventricular Beating-Heart Mitral Valve Repair with Neochordae at 3 Years: Monocentric Retrospective Study
by Alessandro Vairo, Lorenzo Gaiero, Matteo Marro, Caterina Russo, Marco Bolognesi, Paolo Soro, Guglielmo Gallone, Francesco Fioravanti, Paolo Desalvo, Fabrizio D’Ascenzo, Gianluca Alunni, Viviana Sebastiano, Cristina Barbero, Marco Pocar, Gaetano Maria De Ferrari, Mauro Rinaldi and Stefano Salizzoni
J. Clin. Med. 2023, 12(5), 1748; https://doi.org/10.3390/jcm12051748 - 22 Feb 2023
Cited by 2 | Viewed by 1408
Abstract
The NeoChord procedure is an echo-guided trans-ventricular beating-heart mitral valve repair technique to treat degenerative mitral regurgitation (MR) due to prolapse and/or flail. The aim of this study is to analyze echocardiographic images to find pre-operative parameters to predict procedural success (≤moderate MR) [...] Read more.
The NeoChord procedure is an echo-guided trans-ventricular beating-heart mitral valve repair technique to treat degenerative mitral regurgitation (MR) due to prolapse and/or flail. The aim of this study is to analyze echocardiographic images to find pre-operative parameters to predict procedural success (≤moderate MR) at 3-year follow-up. Seventy-two consecutive patients with severe MR underwent the NeoChord procedure between 2015 and 2021. MV pre-operative morphological parameters were assessed using 3D transesophageal echocardiography with dedicated software (QLAB, Philips). Three patients died during their hospitalization. The remaining 69 patients were retrospectively analyzed. At follow-up, MR > moderate was found in 17 patients (24.6%). In the univariate analysis, end-systolic annulus area (12.5 ± 2.5 vs. 14.1 ± 2.6 cm2; p = 0.038), end-systolic annulus circumference (13.2 ± 1.2 vs. 14 ± 1.3 cm; p = 0.042), indexed left atrial volume (59 ± 17 vs. 76 ± 7 mL/m2; p = 0.041), and AF (25% vs. 53%; p = 0.042) were lower in the 52 patients with ≤ MR compared to those with > moderate MR. Annular dysfunction parameters were the best predictors of procedural success: 3D early-systolic annulus area (AUC 0.74; p = 0.004), 3D early-systolic annulus circumference (AUC 0.75; p = 0.003), and 3D annulus area fractional change (AUC 0.73; p = 0.035). Patient selection relying on 3D dynamic and static MA dimensions may improve the maintenance of procedural success at follow-up. Full article
Show Figures

Figure 1

Review

Jump to: Research

9 pages, 537 KiB  
Review
Ten Future Challenges in the Field of Transcatheter Mitral Valve Edge-to-Edge Repair
by Mathias Orban, Ludwig T. Weckbach, Thomas J. Stocker, Philipp M. Doldi, Michael Näbauer, Steffen Massberg, Jörg Hausleiter and Lukas Stolz
J. Clin. Med. 2024, 13(6), 1799; https://doi.org/10.3390/jcm13061799 - 21 Mar 2024
Viewed by 873
Abstract
Mitral valve transcatheter edge-to-edge repair (M-TEER) and replacement (TMVR) have evolved as guideline-recommended treatment approaches for mitral regurgitation (MR). Even though they are supported by a growing body of evidence from either randomized trials or large registries, there are still several unsolved challenges [...] Read more.
Mitral valve transcatheter edge-to-edge repair (M-TEER) and replacement (TMVR) have evolved as guideline-recommended treatment approaches for mitral regurgitation (MR). Even though they are supported by a growing body of evidence from either randomized trials or large registries, there are still several unsolved challenges in the field of interventional MR treatment. In the present review, we discuss the ten most important open questions regarding M-TEER and TMVR. Full article
Show Figures

Figure 1

Back to TopTop